{"id":794945,"date":"2024-12-16T06:03:58","date_gmt":"2024-12-16T11:03:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/"},"modified":"2024-12-16T06:03:58","modified_gmt":"2024-12-16T11:03:58","slug":"serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/","title":{"rendered":"Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0&#8220;Enabling Continuous Drug Delivery for Parkinson&#8217;s Disease &amp; Beyond&#8221; on Wednesday, December 18, 2024"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>Meet with\u00a0<\/em><br \/>\n          <em>Serina<\/em><br \/>\n          <em>\u2019s CEO <\/em><br \/>\n          <em>Steven A. Ledger<\/em>\n        <\/li>\n<li>\n          <em>Parkinson&#8217;s disease is a progressive neurological disorder that primarily affects movement<\/em>\n        <\/li>\n<li>\n          <em>Continuous dopaminergic stimulation (CDS) has been shown to reduce the severity of motor complications (dyskinesia) in advanced Parkinson\u2019s patients<\/em>\n        <\/li>\n<li>\n          <em>Discussion of the Serina IND candidate\u2019s target product profile versus the current standard of care in providing CDS<\/em>\n        <\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>HUNTSVILLE, AL, Dec.  16, 2024  (GLOBE NEWSWIRE) &#8212; <\/strong><br \/>\n        <strong><br \/>\n          <u>Serina Therapeutics, Inc.<\/u><br \/>\n        <\/strong>\u00a0(\u201cSerina\u201d) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform<sup>\u2122<\/sup>\u00a0drug delivery technology, is pleased to announce that Serina\u2019s CEO, Steven A. Ledger will present at Tribe Public\u2019s Webinar Presentation and Q&amp;A Event titled <em>&#8220;Enabling Continuous Drug Delivery for Parkinson&#8217;s Disease &amp; Beyond.\u201d <\/em>The Event is scheduled to begin at 8:30 am pacific \/ 11:30 am eastern on Wednesday, December 18, 2024. To register to join the complimentary event, please visit the Tribe Public LLC at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3soSBgXMzLhJM6xswfxZiHMlKejY0wE3Uas0RSXTUv016zKbNis8ZfcggPnPb0cHn1Cl2kT1vWAG2QUSJ_I5yxXtECupSveDJF2jo7DMzoUwIcKJNtUuDJvHsgcXVzq_\" rel=\"nofollow\" target=\"_blank\">SERDEC2024.TribePublic.com<\/a>.<\/p>\n<p \/>\n<p align=\"justify\">Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hACTSky58N8aInG2RWwVf_XV6ZB7CIRoSQEEqq6QEyxFQNrnzXhKOmKMQwnbZ00TyelKVDQ9AmnevIXJYsKn3aWFir5wZEMKZSK7nh2l8xY=\" rel=\"nofollow\" target=\"_blank\"><u>research@tribepublic.com<\/u><\/a>\u00a0or share their questions via the ZOOM chat feature during the event. Tribe Public\u2019s Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.<\/p>\n<p>\n        <strong>About Serina Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina\u2019s POZ Platform<sup>\u2122<\/sup>\u00a0provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lNDwYaIeYVSG2sHseQ7Y5J0W6SY-alNIgNm9-uG0_xI5SFGJisQliqxdTeiPH9x70JX9rTox6TAPm-6LdVadgH7iOo2vh-m_7BXpXIeTczpMuWoYiWPMFo5c1UG_6_Lw\" rel=\"nofollow\" target=\"_blank\">https:\/\/serinatherapeutics.com<\/a><u>.<\/u><\/p>\n<p>\n        <strong>About Tribe Public LLC<\/strong>\n      <\/p>\n<p align=\"justify\">Tribe Public LLC is a San Francisco, CA based organization that hosts complimentary worldwide webinar &amp; in-person meeting events in the U.S. Tribe\u2019s complimentary events focus on issues that the Tribe members care about with an emphasis on hosting management teams from publicly traded companies from all sectors &amp; financial organizations that are seeking to increase awareness of their products, progress and plans. Tribe members primarily include Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media. Tribe Members are encouraged to express their interest in speakers they care about and want to learn from at the Tribe Public website via the Tribe\u2019s FREE <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DM0J4DP1ruG167kH2v_cREv60dk4H2XQrlJM76NGDQBjZZH9pMWX4YEEBncurYJstekk6ZjhJ_lYJLCuL9Ldrd7v-xb0D6djelbzNcHtk9c=\" rel=\"nofollow\" target=\"_blank\"><u>\u201cWish List\u201d<\/u><\/a> process. Visit Tribe Public\u2019s Website to learn more: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SwutQsaze-vujmVsLLegIIZCR9GT19oTmS9Z3mLXN9mApsKsG2YaC0M2CfxL5FKFYNXWFRYoBAxDkdAquBlTlwZCvtSwqp2zE4GRgvCIqj4=\" rel=\"nofollow\" target=\"_blank\"><u>http:\/\/www.tribepublic.com\/<\/u><\/a><\/p>\n<p>\n        <strong>Cautionary Statement Regarding Forward-Looking Statement<\/strong>\n      <\/p>\n<p align=\"justify\">This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management\u2019s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina\u2019s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and\/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and\/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product\u2019s benefits outweigh its known risks and determination of the product\u2019s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and\/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, the company\u2019s Current Report on Form 8-K that was filed with the SEC on April 1, 2024, and the company\u2019s other periodic reports and documents filed from time to time with the SEC.<\/p>\n<p align=\"justify\">The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.<\/p>\n<p>\n        <strong>For inquiries, please contact:<\/strong><br \/>\n        <br \/>Stefan Riley<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y5k5lVjz61c4KOJsY4dIoHjQH5Slefx2fQW1Y9LQQWPKBJw-xDSywErM-mbWgYBHQ-uG0KZixafOfdD-xfIxQFZ2WQd7ZRlFEXO84pzj5Jc_VSLAWsPRr6PhXm7FYFEw\" rel=\"nofollow\" target=\"_blank\"><strong>sriley@serinatherapeutics.com<\/strong><\/a><br \/>(256) 327-9630<\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/253d12f0-bffc-4a2a-b0be-942af1d68a4b\">Serina Therapeutics, Inc.<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTYwNiM2NjM4NTg1IzUwMDExOTk2NQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjFhMzE0MWQtNGYzZC00N2I3LTk3ZDktODQ5NzI5YTQwM2YyLTUwMDExOTk2NQ==\/tiny\/Serina-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Meet with\u00a0 Serina \u2019s CEO Steven A. Ledger Parkinson&#8217;s disease is a progressive neurological disorder that primarily affects movement Continuous dopaminergic stimulation (CDS) has been shown to reduce the severity of motor complications (dyskinesia) in advanced Parkinson\u2019s patients Discussion of the Serina IND candidate\u2019s target product profile versus the current standard of care in providing CDS HUNTSVILLE, AL, Dec. 16, 2024 (GLOBE NEWSWIRE) &#8212; Serina Therapeutics, Inc. \u00a0(\u201cSerina\u201d) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform\u2122\u00a0drug delivery technology, is pleased to announce that Serina\u2019s CEO, Steven A. Ledger will present at Tribe Public\u2019s Webinar Presentation and Q&amp;A Event titled &#8220;Enabling Continuous Drug Delivery for Parkinson&#8217;s Disease &amp; Beyond.\u201d The Event is scheduled to begin at 8:30 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0&#8220;Enabling Continuous Drug Delivery for Parkinson&#8217;s Disease &amp; Beyond&#8221; on Wednesday, December 18, 2024&#8243;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-794945","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0&quot;Enabling Continuous Drug Delivery for Parkinson&#039;s Disease &amp; Beyond&quot; on Wednesday, December 18, 2024 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0&quot;Enabling Continuous Drug Delivery for Parkinson&#039;s Disease &amp; Beyond&quot; on Wednesday, December 18, 2024 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Meet with\u00a0 Serina \u2019s CEO Steven A. Ledger Parkinson&#8217;s disease is a progressive neurological disorder that primarily affects movement Continuous dopaminergic stimulation (CDS) has been shown to reduce the severity of motor complications (dyskinesia) in advanced Parkinson\u2019s patients Discussion of the Serina IND candidate\u2019s target product profile versus the current standard of care in providing CDS HUNTSVILLE, AL, Dec. 16, 2024 (GLOBE NEWSWIRE) &#8212; Serina Therapeutics, Inc. \u00a0(\u201cSerina\u201d) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform\u2122\u00a0drug delivery technology, is pleased to announce that Serina\u2019s CEO, Steven A. Ledger will present at Tribe Public\u2019s Webinar Presentation and Q&amp;A Event titled &#8220;Enabling Continuous Drug Delivery for Parkinson&#8217;s Disease &amp; Beyond.\u201d The Event is scheduled to begin at 8:30 &hellip; Continue reading &quot;Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0&#8220;Enabling Continuous Drug Delivery for Parkinson&#8217;s Disease &amp; Beyond&#8221; on Wednesday, December 18, 2024&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-16T11:03:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTYwNiM2NjM4NTg1IzUwMDExOTk2NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0&#8220;Enabling Continuous Drug Delivery for Parkinson&#8217;s Disease &amp; Beyond&#8221; on Wednesday, December 18, 2024\",\"datePublished\":\"2024-12-16T11:03:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\\\/\"},\"wordCount\":832,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxOTYwNiM2NjM4NTg1IzUwMDExOTk2NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\\\/\",\"name\":\"Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0\\\"Enabling Continuous Drug Delivery for Parkinson's Disease &amp; Beyond\\\" on Wednesday, December 18, 2024 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxOTYwNiM2NjM4NTg1IzUwMDExOTk2NQ==\",\"datePublished\":\"2024-12-16T11:03:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxOTYwNiM2NjM4NTg1IzUwMDExOTk2NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxOTYwNiM2NjM4NTg1IzUwMDExOTk2NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0&#8220;Enabling Continuous Drug Delivery for Parkinson&#8217;s Disease &amp; Beyond&#8221; on Wednesday, December 18, 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0\"Enabling Continuous Drug Delivery for Parkinson's Disease &amp; Beyond\" on Wednesday, December 18, 2024 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/","og_locale":"en_US","og_type":"article","og_title":"Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0\"Enabling Continuous Drug Delivery for Parkinson's Disease &amp; Beyond\" on Wednesday, December 18, 2024 - Market Newsdesk","og_description":"Meet with\u00a0 Serina \u2019s CEO Steven A. Ledger Parkinson&#8217;s disease is a progressive neurological disorder that primarily affects movement Continuous dopaminergic stimulation (CDS) has been shown to reduce the severity of motor complications (dyskinesia) in advanced Parkinson\u2019s patients Discussion of the Serina IND candidate\u2019s target product profile versus the current standard of care in providing CDS HUNTSVILLE, AL, Dec. 16, 2024 (GLOBE NEWSWIRE) &#8212; Serina Therapeutics, Inc. \u00a0(\u201cSerina\u201d) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform\u2122\u00a0drug delivery technology, is pleased to announce that Serina\u2019s CEO, Steven A. Ledger will present at Tribe Public\u2019s Webinar Presentation and Q&amp;A Event titled &#8220;Enabling Continuous Drug Delivery for Parkinson&#8217;s Disease &amp; Beyond.\u201d The Event is scheduled to begin at 8:30 &hellip; Continue reading \"Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0&#8220;Enabling Continuous Drug Delivery for Parkinson&#8217;s Disease &amp; Beyond&#8221; on Wednesday, December 18, 2024\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-16T11:03:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTYwNiM2NjM4NTg1IzUwMDExOTk2NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0&#8220;Enabling Continuous Drug Delivery for Parkinson&#8217;s Disease &amp; Beyond&#8221; on Wednesday, December 18, 2024","datePublished":"2024-12-16T11:03:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/"},"wordCount":832,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTYwNiM2NjM4NTg1IzUwMDExOTk2NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/","name":"Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0\"Enabling Continuous Drug Delivery for Parkinson's Disease &amp; Beyond\" on Wednesday, December 18, 2024 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTYwNiM2NjM4NTg1IzUwMDExOTk2NQ==","datePublished":"2024-12-16T11:03:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTYwNiM2NjM4NTg1IzUwMDExOTk2NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTYwNiM2NjM4NTg1IzUwMDExOTk2NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-to-present-at-tribe-publics-webinar-event-enabling-continuous-drug-delivery-for-parkinsons-disease-beyond-on-wednesday-december-18-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Serina Therapeutics to Present at Tribe Public\u2019s Webinar Event\u00a0&#8220;Enabling Continuous Drug Delivery for Parkinson&#8217;s Disease &amp; Beyond&#8221; on Wednesday, December 18, 2024"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=794945"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794945\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=794945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=794945"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=794945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}